Could a tailored drug dose cut transfusions for kids with sickle cell?

NCT ID NCT05662098

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving children with sickle cell anemia a personalized dose of hydroxyurea can lower their need for blood transfusions. About 100 children in Uganda will receive a dose based on their own drug levels. Researchers will compare transfusion rates before and during treatment to see if the approach works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hydroxyurea

What this could lead to

If successful, this could show that personalized hydroxyurea dosing reduces the need for blood transfusions in children with sickle cell anemia.

What could go wrong

This is a very early, small study (100 children) without a comparison group, so results may not be conclusive or apply broadly. Hydroxyurea can lower blood counts and cause other side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jinja Regional Referral Hospital (JRRH), Department of Paediatrics, Sickle Cell Clinic

    Jinja, Uganda